IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Debt-to-EBITDA : -2.36 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is IPI Legacy Liquidation Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

IPI Legacy Liquidation Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $112.56 Mil. IPI Legacy Liquidation Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $2.24 Mil. IPI Legacy Liquidation Co's annualized EBITDA for the quarter that ended in Sep. 2023 was $-48.70 Mil. IPI Legacy Liquidation Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -2.36.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for IPI Legacy Liquidation Co's Debt-to-EBITDA or its related term are showing as below:

IMPLQ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.67 Med: -0.42 Max: -0.19
Current: -1.67

During the past 4 years, the highest Debt-to-EBITDA Ratio of IPI Legacy Liquidation Co was -0.19. The lowest was -1.67. And the median was -0.42.

IMPLQ's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs IMPLQ: -1.67

IPI Legacy Liquidation Co Debt-to-EBITDA Historical Data

The historical data trend for IPI Legacy Liquidation Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IPI Legacy Liquidation Co Debt-to-EBITDA Chart

IPI Legacy Liquidation Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Debt-to-EBITDA

-0.19

-0.42

-0.62

IPI Legacy Liquidation Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-EBITDA	Get a 7-Day Free Trial											-0.60	-0.71	-0.58	-0.81	-2.36

Competitive Comparison of IPI Legacy Liquidation Co's Debt-to-EBITDA

For the Biotechnology subindustry, IPI Legacy Liquidation Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IPI Legacy Liquidation Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IPI Legacy Liquidation Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where IPI Legacy Liquidation Co's Debt-to-EBITDA falls into.

IPI Legacy Liquidation Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

IPI Legacy Liquidation Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.541	+	49.645)	/	-81.983
	=	-0.62

IPI Legacy Liquidation Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(112.563	+	2.235)	/	-48.704
	=	-2.36

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.

IPI Legacy Liquidation Co (OTCPK:IMPLQ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

IPI Legacy Liquidation Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of IPI Legacy Liquidation Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IPI Legacy Liquidation Co (OTCPK:IMPLQ) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Elliott Avenue West, Suite 260, Seattle, WA, USA, 98119

Website

https://www.impelpharma.com

Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.

Executives

Vivo Capital Fund Viii, L.p.	10 percent owner	505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Michael Wayne Kalb	officer: CFO	24 LUCILLE LANE, DIX HILLS NY 11746
Darren S Cline	director	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Rajiv Amin	officer: VP, Controller & Interim CFO	C/O IMPEL PHARMACEUTICALS INC., 201 ELLIOTT AVENUE WEST, STE 260, SEATTLE WA 98119
Timothy S Nelson	director	1024 BUBB ROAD, CUPERTINO CA 950144166
Adrian Adams	director, officer: COB, CEO and President	C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355
Venbio Global Strategic Fund Ii L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
5am Opportunities I, L.p.	10 percent owner	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures V, L.p.	10 percent owner	2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kkr Healthcare Strategic Growth Fund L.p.	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Norwest Venture Partners Xiv, Lp	10 percent owner	525 UNIVERSITY AVENUE, SUITE 800, PALO ALTO CA 94301
Kkr Hcsg Gp Llc	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
5am Partners V, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kkr Associates Hcsg L.p.	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019